☆ 4.6 Letter

Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Get Full Text
Add to Collection

Journal

AMERICAN JOURNAL OF HEMATOLOGY
Volume 96, Issue 6, Pages E193-E196

Publisher

WILEY
DOI: 10.1002/ajh.26150

Keywords

-

Categories

Hematology

Funding

  1. NCI NIH HHS [P30 CA008748, K08 CA241400] Funding Source: Medline

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.